A Phase 2 interventional study of Pemetrexed and Gemcitabine in Non-Small-Cell Lung Cancer, sponsored by Eli Lilly and Company. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-06-03.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 173rd largest by enrollment of the 223 interventional ones that give a count, is one of 12 that started in 2007, is one of 128 in phase 2, and was the 41st registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 47 · Phase 4 8
First in 2001; this study’s year is marked. 12 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 64 across the 223 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 227 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 129th largest by enrollment of the 139 interventional ones that give a count, is one of 9 that started in 2007, is one of 73 in phase 2, and was the 43rd registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate Pemetrexed and Gemcitabine Day 1 followed by Gemcitabine Day 8 every 21 days (Arm A) and Pemetrexed and Gemcitabine Day 1 every 14 days (Arm B) in patients with NSCLC. Each agent and sequence has well demonstrated antitumor activity respectively in patients with locally advanced or metastatic NSCLC. Therefore, it is reasonable to investigate the most optimal schedule for this combination, and which combination is associated with the most anti-tumor activity in the phase II arena.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pemetrexed · Drug: Gemcitabine
Drug: Pemetrexed · Drug: Gemcitabine
A: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles B: 500 mg/m2, intravenous (IV), every 14 days x 9 cycles
Also known as: LY231514, Alimta
A: 1250 mg/m2, intravenous (IV) days 1 and 8, every 21 days x 6 cycles B: 1500 mg/m2, intravenous (IV), every 14 days x 9 cycles
Also known as: LY188011, Gemzar
Best Overall Tumor Response
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.
Time frame: baseline and every 14 or 21 day cycle (6-9 cycles), every 6 weeks post-therapy follow-up
Progression Free Survival
baseline to measured progressive disease
Time frame: baseline and every 14 or 21 day cycle (6-9 cycles), every 6 weeks post-therapy follow-up
Time to Progressive Disease
Time to progressive disease not analyzed because trial was stopped early due to low enrollment.
Time frame: baseline and every 14 or 21 day cycle (6-9 cycles), every 6 weeks post-therapy follow-up
Duration of Response
Duration of response was not analyzed because the trial was stopped early due to low enrollment.
Time frame: baseline and every 14 or 21 day cycle (6-9 cycles), every 6 weeks post-therapy follow-up
Time to Treatment Failure
Time to treatment failure was not analyzed because the trial was stopped early due to low enrollment.
Time frame: baseline and every 14 or 21 day cycle (6-9 cycles), every 6 weeks post-therapy follow-up
Overall Survival
Survival time is defined as the time from date of randomization to death due to any cause.
Time frame: baseline and every 14 or 21 day cycle (6-9 cycles), every 6 weeks post-therapy follow-up
| Milestone | 21-Day Cycle | 14-Day Cycle |
|---|---|---|
| Started | 10 | 9 |
| Completed | 10 | 8 |
| Not completed | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.
| participants | 21-Day Cycle | 14-Day Cycle |
|---|---|---|
| Complete Response | 0 | 0 |
| Partial Response | 2 | 0 |
baseline to measured progressive disease
| months | 21-Day Cycle | 14-Day Cycle |
|---|---|---|
| Progression Free Survival | 1.66 (0.69 to 4.30) | 5.04 (1.74 to 5.95) |
Time to progressive disease not analyzed because trial was stopped early due to low enrollment.
No measurements were reported for this outcome.
Duration of response was not analyzed because the trial was stopped early due to low enrollment.
No measurements were reported for this outcome.
Time to treatment failure was not analyzed because the trial was stopped early due to low enrollment.
No measurements were reported for this outcome.
Survival time is defined as the time from date of randomization to death due to any cause.
| months | 21-Day Cycle | 14-Day Cycle |
|---|---|---|
| Overall Survival | 5.1 (2.4 to 14.2) | 8.1 (5.5 to 10.1) |
Non-serious events are listed at a 15% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 21-Day Cycle | — | — | — |
| 14-Day Cycle | — | — | — |
| Event | 21-Day Cycle | 14-Day Cycle |
|---|---|---|
| FatigueGeneral disorders | 0/10 | 2/9 |
| NeutropeniaBlood and lymphatic system disorders | 2/10 | 2/9 |
| Disease Progression - DeathNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/10 | 0/9 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/10 | 0/9 |
| Ischemia-CerebralNervous system disorders | 1/10 | 0/9 |
| LeukopeniaBlood and lymphatic system disorders | 1/10 | 0/9 |
| Pain - ExtremityGeneral disorders | 1/10 | 0/9 |
| AnemiaBlood and lymphatic system disorders | 1/10 | 0/9 |
| Event | 21-Day Cycle | 14-Day Cycle |
|---|---|---|
| AnemiaBlood and lymphatic system disorders | 8/10 | 8/9 |
| LeukopeniaBlood and lymphatic system disorders | 8/10 | 8/9 |
| NauseaGastrointestinal disorders | 5/10 | 7/9 |
| ThrombocytopeniaBlood and lymphatic system disorders | 7/10 | 2/9 |
| NeutropeniaBlood and lymphatic system disorders | 6/10 | 6/9 |
| FatigueGeneral disorders | 6/10 | 4/9 |
| Pneumonia NOSRespiratory, thoracic and mediastinal disorders | 0/10 | 4/9 |
| Diarrhea-No ColostomGastrointestinal disorders | 4/10 | 2/9 |
| AnorexiaPsychiatric disorders | 2/10 | 3/9 |
| ConstipationGastrointestinal disorders | 3/10 | 1/9 |
| Age Continuous(years) | 21-Day Cycle | 14-Day Cycle | Total |
|---|---|---|---|
| Median | 70.5 (60.0 to 81.0) | 63.0 (48.0 to 74.0) | 66.0 (48.0 to 81.0) |
| Sex: Female, Male(Participants) | 21-Day Cycle | 14-Day Cycle | Total |
|---|---|---|---|
| Female | 5 | 3 | 8 |
| Male | 5 | 6 | 11 |
| Region of Enrollment(participants) | 21-Day Cycle | 14-Day Cycle | Total |
|---|---|---|---|
| United States | 10 | 9 | 19 |
| Eastern Cooperative Oncology Group Performance Score(participants) | 21-Day Cycle | 14-Day Cycle | Total |
|---|---|---|---|
| 0 - Fully Active | 4 | 4 | 8 |
| 1 - Ambulatory, Restricted Strenuous Activity | 6 | 5 | 11 |
| 2 - Amublatory, No Work Activities | 0 | 0 | 0 |
| 3 - Partially Confined to Bed, Limited Self Care | 0 | 0 | 0 |
| 4 - Completely Disabled | 0 | 0 | 0 |
| Previous Radiation Therapy(participants) | 21-Day Cycle | 14-Day Cycle | Total |
|---|---|---|---|
| Yes | 3 | 1 | 4 |
| No | 7 | 8 | 15 |
| Stage of Lung Cancer(participants) | 21-Day Cycle | 14-Day Cycle | Total |
|---|---|---|---|
| IIIB with pleural effusion | 2 | 2 | 4 |
| IV | 8 | 7 | 15 |
| Tumor Cell Type(participants) | 21-Day Cycle | 14-Day Cycle | Total |
|---|---|---|---|
| Squamous | 1 | 2 | 3 |
| Adenocarcinoma | 5 | 3 | 8 |
| Non-Small Cell Lung, Not Otherwise Specified (NOS) | 4 | 2 | 6 |
| Other | 0 | 2 | 2 |
The record gives a start of Feb 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2009, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Gemcitabine
Carcinoma, Non-Small-Cell Lung →